Browsing by Author "Bellosillo Paricio, Beatriz"

Sort by: Order: Results:

  • Van Emburgh, Beth O.; Vidal Barrull, Joana; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Montagut Viladot, Clara; Bardelli, Alberto (Nature Publishing Group, 2016)
    Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of ...
  • Fernández Rodríguez, M. Concepción; Salar Silvestre, Antonio; Navarro, Alfons; Gimeno Vázquez, Eva; Pairet García, Silvia; Camacho Díaz, Laura; Ferraro Rosset, Mariana Paola; Serrano Figueras, Sergi; Besses Raebel, Carles; Bellosillo Paricio, Beatriz; Sanchez Gonzalez, Blanca (Taylor & Francis, 2016)
    Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. ...
  • Margalef González, Pol, 1985-; Colomer Montañà, Carlota, 1990-; Villanueva, Alberto; Montagut Viladot, Clara; Iglesias Coma, Mar; Bellosillo Paricio, Beatriz; Salazar, Ramón; Martínez Iniesta, María; Bigas Salvans, Anna; Espinosa Blay, Lluís (American Association for the Advancement of Science, 2015)
    KRAS mutations contribute to cell proliferation and survival in numerous cancers, including colorectal cancers (CRC). One pathway through which mutant KRAS acts is an inflammatory pathway that involves the kinase IKK and ...
  • Angona Figueras, Anna; Álvarez Larrán, Alberto; Bellosillo Paricio, Beatriz; Longarón Rozalen, Raquel; Camacho Díaz, Laura; Fernández Rodríguez, M. Concepción; Pairet García, Silvia; Besses Raebel, Carles (Elsevier, 2016)
    Mutations in JAK2 or CALR are observed in patients with myeloproliferative neoplasms (MPN). To get further insight in the dynamics of the mutant clone, we assessed the mutant allele burden in hematopoietic stem cells (HSCs), ...
  • Gallardo Hernández, Fernando; Padrón, Andreina; Garcia Carbonell, Ricard; Rius, Cristina; González-Pérez, Abel; Arumí, Montserrat; Iglesias Coma, Mar; Nonell Mazelón, Lara; Bellosillo Paricio, Beatriz; Segura Tigell, Sonia; Pujol Vallverdú, Ramon Maria; López Bigas, Núria; Bertran, Joan; Bigas Salvans, Anna; Espinosa Blay, Lluís (Impact Journal, 2015)
    Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential regulator of gene transcription, and its function has been found ...
  • Casadevall Aguilar, David; Vidal Barrull, Joana; Gallardo Hernández, Fernando; Zuccarino, Flavio; Arumí, Montserrat; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Montagut Viladot, Clara (BioMed Central, 2016)
    BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 ...
  • López Trujillo, Emilio; Gonzàlez Farré, Mònica; Pujol, Ramón M.; Bellosillo Paricio, Beatriz; Fisa, Roser; Riera Carro, Cristina; Alcover, Magdalena; Barranco Sanz, Luis Carlos; Martin-Ezquerra, Gemma (Histology and Histopathology, 2021)
    Background: Different immunohistochemical markers to detect amastigotes in cutaneous leishmaniasis have been proposed with variable diagnostic usefulness. Objectives: To evaluate the diagnostic usefulness of immunohistochemical ...
  • López-Aventín, Daniel; Gallardo Hernández, Fernando; Colomo Saperas, Luis Alberto; Moragón, Ester; Vela Ortíz, María del Carmen; Duran Jordà, Xavier, 1974-; Bellosillo Paricio, Beatriz; Pujol Vallverdú, Ramon Maria (Society for Publication of Acta Dermato-Venereologica, 2021)
    BIOMED-2 Concerted Action BMH4-CT98-3936 (BIOMED-2) PCR protocols are an important diagnostic tool in the evaluation of cutaneous lymphomas. The aim of this study was to assess the diagnostic value of the genotyping results ...
  • Ortmann, Christina A.; Green, Anthony R.; Bellosillo Paricio, Beatriz; Besses Raebel, Carles (Massachusets medical society, 2015)
    BACKGROUND: Cancers result from the accumulation of somatic mutations, and their properties are thought to reflect the sum of these mutations. However, little is known about the effect of the order in which mutations are ...
  • Chalela Rengifo, Roberto José, 1985-; González-García, José Gregorio; Khilzi, Karys; Curull Serrano, Víctor; Sánchez Font, Albert; Longarón Rozalen, Raquel; Rodrigo Calvo, Maria Teresa; Martín-Ontiyuelo, Clara; Gea Guiral, Joaquim; Bellosillo Paricio, Beatriz (Frontiers, 2021)
    The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present ...
  • Chalela Rengifo, Roberto José, 1985-; Bellosillo Paricio, Beatriz; Curull Serrano, Víctor; Longarón Rozalen, Raquel; Pascual Guàrdia, Sergi, 1979-; Badenes Bonet, Diana; Arriola Aperribay, Edurne; Sánchez-Font, Albert; Pijuan Andujar, Lara; Gea Guiral, Joaquim (MDPI, 2019)
    Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout ...
  • Martínez-Calle, Nicolás; Pascual, Marien; Ordóñez, Raquel; San José-Enériz, Edurne; Kulis, Marta; Miranda, Estíbaliz; Guruceaga, Elisabeth; Segura, Víctor; Larráyoz, María José; Bellosillo Paricio, Beatriz; Calasanz, María José; Besses Raebel, Carles; Rifón, José; Martín-Subero, José I.; Agirre, Xabier; Prosper, Felipe (Ferrata Storti Foundation, 2019)
    In this study we have interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpGs corresponding to 10,253 genes between myelofibrosis ...
  • Brammeld, Jonathan S.; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Vidal Barrull, Joana; Montagut Viladot, Clara; McDermott, Ultan (Cold Spring Harbor Laboratory Press (CSHL Press), 2017)
    Drug resistance is an almost inevitable consequence of cancer therapy and ultimately proves fatal for the majority of patients. In many cases, this is the consequence of specific gene mutations that have the potential to ...
  • Alvarez-Larrán, Alberto; Díaz-González, Alvaro; Such, Esperanza; Mora, Elvira; Andrade-Campos, Marcio; García-Hernández, Carmen; Gómez-Casares, Maria-Teresa; García-Gutiérrez, Valentín; Carreño-Tarragona, Gonzalo; Garrote, Marta; Fernández-Ibarrondo, Lierni; Cervera, José; Bellosillo Paricio, Beatriz; Cervantes, Francisco; Hernández-Boluda, Juan Carlos; MPN Spanish Group (GEMFIN) (Nature Research, 2020)
  • Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...
  • Robles, Eloy F.; Bellosillo Paricio, Beatriz; Salar Silvestre, Antonio; Martinez-Climent, Jose A. (Nature Publishing Group, 2016)
    NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. ...
  • Berghoff, Anna S.; Bellosillo Paricio, Beatriz; Caux, Christophe; de Langen, Adrianus; Mazieres, Julien; Normanno, Nicola; Preusser, Matthias; Provencio, Mariano; Rojo, Federico; Wolf, Jurgen; Zielinski, Christoph C. (BMJ Publishing Group, 2019)
    The introduction of targeted treatments and more recently immune checkpoint inhibitors (ICI) to the treatment of metastatic non-small cell lung cancer (NSCLC) has dramatically changed the prognosis of selected patients. ...
  • Alvarez-Larrán, Alberto; Senín Magan, Maria Alicia; Fernández Rodríguez, M. Concepción; Pereira, Arturo; Arellano-Rodrigo, Arturo; Gómez, Montse; Ferrer-Marín, Francisca; Martínez-López, Joaquín; Camacho Díaz, Laura; Colomer, Dolors; Angona Figueras, Anna; Navarro, Blanca; Cervantes, Francisco; Besses Raebel, Carles; Bellosillo Paricio, Beatriz; Hernández-Boluda, Juan Carlos (Wiley, 2017)
    The influence of driver mutations on leukaemic transformation was analysed in 1747 patients with polycythaemia vera or essential thrombocythaemia. With a median follow-up of 7·2 years, 349 patients died and 62 progressed ...
  • Asp, Julia; Bellosillo Paricio, Beatriz; Pallisgaard, Niels (SpringerOpen, 2019)
    External quality assurance (EQA) programs are vital to ensure high quality and standardized results in molecular diagnostics. It is important that EQA for quantitative analysis takes into account the variation in methodology. ...
  • Remon, Jordi; García-Campelo, R.; Álava, Enrique de; Vera, R.; Rodríguez Peraltó, José Luís; Rodríguez-Lescure, Á.; Bellosillo Paricio, Beatriz; Garrido, P.; Rojo, Federico; Álvarez-Alegret, R. (Springer, 2020)
    The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of ...